High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
Poster presentation details are as follows:
Title: The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical Implications
Session Category/Title: P1.14/Targeted Therapy Session
Session Date and Time: Sunday September 8, 2019,
Location: Fira Gran Via Conference Center, Exhibit Hall, Poster Session P1.14
"To date, our clinical experience has demonstrated consistent performance for detecting actionable mutations in the ctDNA of patients with NSCLC as low as 0.01% mutant allele frequency," said
"We are very pleased to highlight the robust real-world performance of our Target Selector™ ctDNA assays for lung cancer, as well as the utility of our CEE-Sure™ blood collection tubes at this year's
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to the ability of our collection tube technology to contribute to a higher level of sensitivity in liquid biopsy testing, the clinical benefits of our proprietary molecular diagnostic technologies and services, our ability to improve the management, diagnosis and treatment of cancer, and the ability of our tests to provide clinically actionable information to oncologist and their patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/high-sensitivity-of-biocepts-target-selector-platform-using-cee-sure-blood-collection-tubes-to-be-featured-in-poster-presentation-at-the-2019-iaslc-world-conference-on-lung-cancer-300905630.html
SOURCE